制备并表征了一系列具有不同取代基的N-(烷基或TMS)-2-吡啶胺乙基铝配合物。当取代基为正丙基和正丁基时,N-(烷基或TMS)-2-吡啶胺二乙基铝络合物在-30°C时发生团聚。相反,当取代基是异丙基和三甲基甲硅烷基时,不容易观察到附聚物。与N-(烷基或TMS)异丙基,三甲基甲硅烷的-2-吡啶胺二乙基铝配合物,和异丙基,所比较的1N-(正丙基)-2-吡啶氨基氨基二乙基铝的吡啶部分的1 H NMR谱具有三组峰。多余的峰可能来自二聚体和三聚体。由于季环的高张力和吡啶对键合的影响,吡啶不参与配位,优化的单体结构决定了该单体不是季环结构。考虑到N-(正丙基)-2-吡啶氨基氨基二乙基铝的液体产物在-30℃下快速缩合,通过可变温度NMR和模拟NMR确定在不同温度下化合物2的存在形式。当温度达到60°C时,N-(n-丙基)-2-吡啶氨基二乙基铝是单体(由甲苯形成的稳定结构)。在-30°C下,单体从与甲苯
[EN] N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS D'ACIDES AMINÉS N-ACYLE ET MÉTHODES D'UTILISATION
申请人:PLIANT THERAPEUTICS INC
公开号:WO2018049068A1
公开(公告)日:2018-03-15
The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:US20160095858A1
公开(公告)日:2016-04-07
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R
1
, R
2
, R
3
, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
[EN] IMMUNOPHILIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À L'IMMUNOPHILINE ET LEURS UTILISATIONS
申请人:UNIV CALIFORNIA
公开号:WO2020163594A1
公开(公告)日:2020-08-13
Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
A cationic Ir(I)–tolBINAP complex catalyzed an enantioselective C–C bond formation, which was initiated by secondary sp3 C–H bondcleavage adjacent to nitrogen atom. A wide variety of 2-(alkylamino)pyridines and alkenes were selectively transformed into the corresponding chiral amines with moderate to almost perfect enantiomeric excesses. Alkynes were also investigated as coupling partners. The effect
New benzimidazolium sulfonate salts have been prepared and fully characterized. They have been associated in situ with [RuCl2(p-cymene)]2 to generate efficient catalytic systems operating at 120 °C under neat conditions in the presence of potassium tert-butylate for selective N-alkylation of primary aromatic amines into secondary amines.